JNCE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2023 @ 22:00):

Stats
Dagens volum	11.60M
Gjennomsnittsvolum	3.47M
Markedsverdi	98.95M
EPS	$0 ( 2024-03-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.958
ATR14	$0.0820 (4.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-03	Concentra Biosciences, Llc	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Sell	5 300 087	Common Stock
2023-05-03	Concentra Biosciences, Llc	Buy	0	Common Stock
2023-05-03	Salter-cid Luisa	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-96.66
Last 98 transactions
Buy: 1 025 987 \| Sell: 8 913 091

Volum Korrelasjon

Lang: -0.01 (neutral)

Kort: -0.19 (neutral)

Signal:(59.515) Neutral

Jounce Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
SVAC	0.941
MLAI	0.934
QADB	0.93
DXPE	0.928
MPRA	0.928
IMPPP	0.928
SGC	0.924
VITL	0.924
IVCB	0.924
AIRG	0.923

10 Mest negative korrelasjoner
LWAC	-0.964
FRBA	-0.956
AMAL	-0.953
CCB	-0.953
CVBF	-0.95
RETO	-0.95
BIVI	-0.948
RBB	-0.946
FBMS	-0.946
MYFW	-0.944

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Jounce Therapeutics Inc Korrelasjon - Valuta/Råvare

0.45
( neutral )

0.82
( strong )

0.00
( neutral )

0.28
( neutral )

-0.21
( neutral )

-0.72
( moderate negative )

Jounce Therapeutics Inc Økonomi

Annual	2022
Omsetning:	$82.00M
Bruttogevinst:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2022
Omsetning:	$82.00M
Bruttogevinst:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2021
Omsetning:	$26 907.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.00182

FY	2020
Omsetning:	$62.34M
Bruttogevinst:	$62 339.00 (0.10 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.